• Earlier this week, the American Cancer Society updated its colorectal cancer screening guidelines, reaffirming Abbott’s Cologuard and Cologuard Plus as preferred noninvasive options for average‑risk adults aged 45 and older on a three‑year testing interval.
• The endorsement, combined with Abbott’s planned commercialization of a blood‑based colorectal cancer test pending FDA approval, reinforces its broad footprint across noninvasive cancer screening.
• We’ll now explore how reaffirmed ACS guideline preference for Cologuard and Cologuard Plus influences Abbott’s broader investment narrative and growth drivers.

AI is about to change healthcare. These 37 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

Abbott Laboratories Investment Narrative Recap

To own Abbott today, I think you need to believe in its ability to convert a broad, innovation‑driven healthcare portfolio into steady earnings growth, despite recent share price underperformance and diagnostics headwinds. The ACS decision on Cologuard and Cologuard Plus supports Abbott’s noninvasive cancer screening ambitions, but it does not materially change the near term focus on stabilizing diagnostics revenue and managing pricing pressure in key markets such as China.

The recent ACS guideline reaffirmation fits alongside Abbott’s CE‑marked Libre Duo glucose ketone sensors, which also target large, chronic disease markets with recurring testing needs. Together, these developments highlight how new products in diagnostics and devices could offset lingering pressure from declining COVID testing, foreign exchange headwinds and competitive bidding in core franchises.

Yet, even as cancer screening and diabetes devices expand, investors should still be aware of how prolonged price pressure in China could...

Abbott Laboratories' narrative projects $59.7 billion revenue and $9.5 billion earnings by 2029. This requires 9.7% yearly revenue growth and about a $3.2 billion earnings increase from $6.3 billion today.

Uncover how Abbott Laboratories' forecasts yield a $118.64 fair value, a 39% upside to its current price.

Exploring Other Perspectives

Five members of the Simply Wall St Community value Abbott between US$118.64 and US$135.74 per share, showing a fairly tight cluster of views. Against that, ongoing diagnostics headwinds and China volume based procurement risks may still shape how comfortably Abbott can grow into those expectations, so it is worth weighing several perspectives before deciding how you see the story.

Explore 5 other fair value estimates on Abbott Laboratories - why the stock might be worth just $118.64!

Decide For Yourself

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Abbott Laboratories research is our analysis highlighting 5 key rewards and 2 important warning signs that could impact your investment decision.
• Our free Abbott Laboratories research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Abbott Laboratories' overall financial health at a glance.

Seeking Other Investments?

Don't miss your shot at the next 10-bagger. Our latest stock picks just dropped:

• Uncover the next big thing with 23 elite penny stocks that balance risk and reward.
• Explore 29 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research.
• Invest in the nuclear renaissance through our list of 88 elite nuclear energy infrastructure plays powering the global AI revolution.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.